• If you are wondering whether Corcept Therapeutics at US$74.89 still offers value after its recent run, this breakdown will help you see how the current price lines up against several valuation yardsticks.
• The stock has moved sharply in the short term, with returns of 9.5% over 7 days, 45.9% over 30 days, 96.0% year to date, and 8.5% over the last year, while longer term returns over 3 and 5 years stand at 211.5% and 248.0% respectively.
• Recent coverage of Corcept Therapeutics has focused on its position in the pharmaceuticals space and how investors are reacting to its latest business updates. These headlines give useful context for the recent price moves, especially for readers weighing whether sentiment has run ahead of fundamentals or not.
• On Simply Wall St's valuation checks, Corcept Therapeutics currently scores 2 out of 6. The next sections will break down what different methods like DCF and multiples are implying about fair value, and then finish with a broader way to think about valuation that goes beyond the numbers alone.

Corcept Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corcept Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting them back to today’s value. It is essentially asking what those future dollars are worth in today’s terms.

For Corcept Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow stands at about $119.40 million. Analysts and internal estimates project Free Cash Flow figures through to 2035, with Simply Wall St extrapolating beyond the initial analyst horizon. For example, projected Free Cash Flow for 2030 is $303.00 million, with discounted values provided for each year, such as $100.83 million in 2026 and $214.95 million in 2030.

Bringing all of those projected cash flows back to today, the DCF output suggests an intrinsic value of $83.61 per share. Compared to the current share price of $74.89, this indicates that the stock trades at about a 10.4% discount on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corcept Therapeutics is undervalued by 10.4%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Corcept Therapeutics Price vs Sales

For profitable companies, price based on sales, or the P/S ratio, is a useful way to see how much investors are paying for each dollar of revenue, especially when earnings can be influenced by accounting items or one off factors.

In simple terms, higher growth expectations and lower perceived risk can support a higher “normal” P/S ratio, while slower expected growth or higher risk typically line up with a lower multiple. This is why comparing P/S in isolation can be misleading.

Corcept Therapeutics currently trades on a P/S ratio of 10.45x. That sits above the Pharmaceuticals industry average of about 5.70x and also above the peer average of 5.86x. To refine this view, Simply Wall St uses a proprietary “Fair Ratio” of 15.35x for Corcept Therapeutics, which reflects factors such as its growth profile, profit margins, industry, market cap and company specific risks.

This Fair Ratio aims to be more tailored than a blunt peer or industry comparison because it adjusts for those company level characteristics rather than assuming all stocks should trade on the same multiple. When compared with the current P/S of 10.45x, the Fair Ratio of 15.35x indicates that Corcept Therapeutics trades below this model based estimate.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Corcept Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Corcept Therapeutics with specific forecasts and a Fair Value. For example, one investor might lean toward a more upbeat story that lines up with a Fair Value around US$121.00 based on higher revenue and earnings assumptions. Another might prefer a more cautious story closer to US$44.00 that reflects concerns around Korlym reliance, legal risk and execution. As news or earnings arrive, the platform refreshes those Narratives so you can easily compare each Fair Value with the current price and decide whether the stock looks closer to fully priced or still attractive, all within a simple Community page used by millions of investors.

For Corcept Therapeutics, here are previews of two leading Corcept Therapeutics Narratives.

Fair Value: US$121.00

Implied discount to this Fair Value: about 38% compared to the latest close around US$74.89

Revenue growth assumption: about 37.5% a year

• Supports a higher Fair Value by assuming rapid revenue growth, a significant increase in profit margins and earnings reaching US$708.3 million by around 2029.
• Relies on multiple late-stage drugs like relacorilant, miricorilant and dazucorilant gaining approvals across endocrine, oncology, MASH and ALS to broaden revenue sources.
• Requires comfort with higher regulatory, legal and execution risks, because setbacks in patents, approvals or uptake would weaken this more optimistic view.

Fair Value: US$73.40

Implied premium to this Fair Value: about 2% compared to the latest close around US$74.89

Revenue growth assumption: about 27.5% a year

• Bases the Fair Value on a consensus-style view that already factors in solid revenue and margin expansion but at a lower P/E multiple by 2029.
• Highlights heavy dependence on Korlym, ongoing patent disputes and pricing pressure as key threats to earnings quality and diversification.
• Flags regulatory and commercial execution risks around the broader pipeline that could limit how much value new indications and products ultimately add.

If you want to see how other investors are connecting these numbers to their own expectations for growth, risk and Fair Value, To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Corcept Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.